NATIVE (Nash Trial to validate IVA337 Efficacy) Phase IIb trial
FASST (For A Systemic Sclerosis Treatment) Phase IIb trial
Systemic sclerosis (SSc) is a complex, multiorgan, rare disease, affecting the immune system, the microvascular system and the connective tissue. This disease involves mostly the skin but also lung, heart, gastrointestinal tract and kidneys. Organ progressive failures make SSc a severe and lethal disease with a high death toll.
FASST study is designed to compare for 48 weeks two doses of IVA337 with a placebo control level. The study is currently recruiting in 8 European countries and more than 50 centers have been selected.
The primary end point will be the mean change of the MRSS (Modified Rodnan Skin score) from baseline to 48 weeks.
For further information on the FASST clinical trial and to watch a video of Professor Yannick Allanore performing the MRSS score, please visit www.fassttrial.com